QUEST® PLUS Gel from Zoetis Approved for Use in Broodmares
Extended approval shows QUEST PLUS is safe for pregnant and lactating mares
FLORHAM PARK, N.J., Feb. 2, 2016 – The U.S. Food and Drug Administration (FDA) has approved QUEST® PLUS Gel from Zoetis for use in breeding, pregnant and lactating mares.
With this latest approval, QUEST PLUS joins QUEST® Gel as approved for use in breeding mares. QUEST PLUS and QUEST meet the individual needs of horses as outlined in the American Association of Equine Practitioners (AAEP) Parasite Control Guidelines. QUEST PLUS and QUEST are the only FDA-approved dewormers on the market that treat and control encysted small strongyles and bots in a single dose. QUEST PLUS also treats and controls tapeworms, to help meet your horse's individual deworming needs.
“The AAEP recommends treatment for tapeworms in late fall after a hard freeze,” said Kenton Morgan, DVM, Equine Technical Services, Zoetis. “For effective treatment, horse owners should consult with their veterinarian and plan to deworm following a hard freeze in order to target tapeworms.”
QUEST originally launched in 1997 and continues to effectively treat parasites in horses. In 2015, more than 1 million doses of QUEST PLUS and QUEST were sold in the United States, and more than 9 million doses have been sold in the U.S. since 2004.1
To purchase QUEST PLUS and QUEST, please visit your local retailer or veterinarian. Prior to purchasing a dewormer, ask your veterinarian to conduct a fecal egg count test. Then evaluate your horse’s Individualized Deworming™ needs by answering a few questions, available at www.idmyhorse.com.
IMPORTANT SAFETY INFORMATION: Do not use QUEST Gel or QUEST PLUS Gel in foals less than 6 months of age or in sick, debilitated and underweight horses. Do not use in other animal species, as severe adverse reactions, including fatalities in dogs, may result.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetisUS.com.
For Further Information,Contact:
1 QUEST PLUS and QUEST Sales Data. Zoetis. December 2015.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States